International Journal of Pharmacy and Pharmaceutical Science

ISSN Print: 2664-7222
ISSN Online: 2664-7230
IJPPS 2025; 7(2): 307-312
www.pharmacyjournal.org
Received: 20-06-2025
Accepted: 28-07-2025

PT Nagaraju
Department of Pharmaceutical Analysis, Dr. K.V. Subba Reddy Institute of Pharmacy, Dupadu, Kurnool, Andhra Pradesh, India

Tekuru Mayuri
Student, Dr. K.V. Subba Reddy Institute of Pharmacy Dupadu, Kurnool, Andhra Pradesh, India

Corresponding Author:
PT Nagaraju
Department of Pharmaceutical Analysis, Dr. K.V. Subba Reddy Institute of Pharmacy, Dupadu, Kurnool, Andhra Pradesh, India

Review article on impurity profiling

PT Nagaraju and Tekuru Mayuri

DOI: https://doi.org/10.33545/26647222.2025.v7.i2d.223

Abstract
Impurity profiling is a critical element of pharmaceutical quality control, fastening on the identification, characterization, and quantification of unwanted substances present in medicine substances and products. contaminations may arise from colourful stages of medicine development, including conflation, expression, storehouse, and transportation, potentially impacting safety, efficacity, and nonsupervisory compliance. They can be astronomically classified as organic, inorganic, or residual detergents, each with distinct sources similar as interceders, by-products, declination pathways, and packaging relations. International guidelines issued by International Council on Harmonization, Food and Drug Administration, and pharmacopoeias set strict limits on permissible contamination situations, icing patient safety and product thickness. ultramodern logical and separation ways similar as High-Performance Liquid Chromatography, Gas Chromatography-Mass Spectrometry, Liquid Chromatography-Mass Spectrometry, Nuclear Magnetic Resonance spectroscopy, Infrared spectroscopy, and UV-Visible spectroscopy play essential places in detecting, segregating, and structurally expounding contaminations. Stability testing, including long-term, accelerated, and forced declination studies, provides perceptivity into declination pathways and supports expression optimization. Qualification and reporting of contaminations further establish toxicological adequacy and nonsupervisory compliance. By applying robust contamination profiling, manufacturers can enhance process control, ameliorate expression stability, and reduce the threat of adverse goods. Accordingly, contamination profiling not only safeguards public health but also facilitates briskly nonsupervisory blessing, cost-effective manufacturing, and the development of safer, more effective pharmaceutical products. This comprehensive approach underscores its significance as a necessary tool for the pharmaceutical assiduity.

Keywords: Impurity profiling, pharmaceutical quality control, Stability testing, Regulatory compliance, analytical techniques, degradation pathways

Introduction
Although they probably are few and far between, unwanted substances might find their way in pharmaceutical products. These unwanted substances may clutter a drug synthesis reaction during preparation, formulation, storage, or transport issues and thus impair the safety, quality, and efficacy of drugs. The impurity profile comprises known and unknown impurities.
Modern analytical techniques such as HPLC, MS, and NMR are in common use for the detection, isolation, and characterization of these impurities.
The regulatory authorities, including the US FDA, EMA, and WHO, and by pharmacopoeias like BP, EP, IP, JP, USP, have titled strict limits on impurities. Based to the ICH guidelines, all impurities found in a drug at levels of 0.10% or higher need to be identified, characterized, and qualified to ensure patient safety and regulatory compliance [1]

Definition: Impurities are unwanted substances present alongside the drug sustenance. These can come together with starting materials, reagents, or catalysts or raw materials, which lend impurities from intermediates formed during synthesis or by compounds generated during storage or transportation [2].

Common Terminology of Impurities [3]
The following important terms are defined by ICH and nonsupervisory bodies

- **Intermediates:** Temporary substances produced during the conflation process are known as intercedes.
- **Penultimate Intermediate:** The last intermediate before the final product is known as the penultimate intermediate.
- **By-products:** Unintentional composites produced by side or ancillary processes.
- **Transformation Products:** The Transformation Products response products linked to the primary patch, either anticipated or unanticipated.
- **Interaction Products:** Created when different chemicals come into contact with one another during the product or storehouse stages.
- **Related Products:** Analogous particulars substances that are chemically analogous to the medicine substance and may have natural exertion as well.
- **Degradation Products:** Declination Products Substances created when the drug or excipients break down as a result of exposure to heat, light, humidity, or time.

Source of Impurities [4, 5]

- **Impurities related to crystallization:** Sources of contaminations Crystallization (Polymorphism/Solvatomorphism) Different demitasse forms or solvates of the same emulsion can introduce contaminations
- **Impurities related to stereochemistry:** Stereochemistry Isomers with the same chemical composition but different spatial arrangements may act as contaminations.
- **Impurities arising from storage:** Storehouse/Transportation contaminations can strain from packaging accoutrements (glass, rubber, plastics); essence oxides like NaO_2, SiO_2, CaO_2 MgO are common
- **Interactions among ingredients:** The component relations Vitamins and other sensitive composites may degrade or lose energy over time in phrasings
- **Residual solvents:** Residual Detergents unpredictable detergents used in manufacturing may remain; detected by gas chromatography due to their unpredictable nature
- **Intermediates and by-products from synthesis:** Conflation interceders By-products Raw accoutrements, detergents, and intercedes may carry over into the final product, creating contaminations
- **Impurities from formulation:** Expression-related Excipients or processing conditions can degrade APIs, especially in results and dormancies
- **Impurities linked to functional groups:** Functional Groups medicines with esters or phenolic groups may suffer hydrolysis or oxidation (e.g., aspirin, catecholamines)
- **Impurities from degradation:** Declination Products APIs like penicillin's and cephalosporins degrade due to β-lactam ring insecurity
- **Method-related impurities:** System-related Manufacturing way (e.g., autoclaving diclofenac sodium) can produce new contaminations similar as indolinone derivations.

Types of Impurities [4, 5]

Pharmaceutical contaminations are astronomically classified into Process/conflation-related expression-related declination-related Main orders as per ICH guidelines

1. Organic impurities (either process-related or drug-related)
2. Inorganic impurities
3. Residual solvents



Fig 1: Types of Impurities

1. **Organic impurities (either process-related or drug-related):** It appear from starting accoutrements, interceders, by-products, or declination during conflation/storehouse. Can be linked/unidentified, unpredictable/non-volatile. Exemplifications residual unreacted starting accoutrements, enantiomeric contaminations, declination products formed during storehouse or expression.
2. **Inorganic impurities:** It appear from manufacturing processes. Sources include Reagents, ligands, catalysts (if not completely removed). Heavy essence (from water, reactors). Sludge aids watercolour (fibres or dark patches). Preventative way demineralized water, glass-lined reactors, routine examination.
3. **Residual solvents:** Organic or inorganic liquids used during manufacturing may be delicate to remove. Classified by toxin Class 1(poisonous, avoid) Benzene (limit 2 ppm), Carbon tetrachloride (4 ppm). Class 2 (limited use) Methylene chloride (600 ppm), Methanol (3000 ppm), Pyridine (200 ppm), Toluene (890 ppm), Acetonitrile (410 ppm). Class 3 (low tox ↓ Acetic acid, Acetone, IPA, Butanol, Ethanol, Ethyl acetate (maximum 50 mg/day).

ICH Guidelines [4-6]

ICH (International Council on Harmonization) brings together nonsupervisory agencies from Europe, Japan, and the U.S. to regularize scientific and specialized conditions for medicine enrolment. It issues crucial guidelines for contamination profiling Main ICH Guidelines on contaminations.

1. **Impurities in New Drug Substances Q3A (R2):** Q3A (R2) contaminations in New Drug Substances Focuses on contaminations in new chemically synthesized medicine substances. Covers organic, biotech-deduced peptides, oligonucleotides, radio pharmaceuticals, turmoil/semi-synthetic products. Excludes beast/factory raw accoutrements.
2. **Impurities in New Drug Products:** Q3B (R2) contaminations in New Drug Products Deals with contaminations in new pharmaceutical products made from chemically synthesized composites. Covers excipients and factors of immediate vessel check systems.
3. **Impurities: Residual Solvent Guidance Q3B (R5):** Q3C/Q3B(R5) Residual Detergents Guidance defines admissible limits for residual detergents to ensure patient safety. Promotes use of lower poisonous detergents and sets respectable situations from a toxicological perspective.
4. **The Guideline for Elemental Impurities Q3D**: Q3D Essential contaminations Guideline Focuses on essential(essence) contaminations in new or reformulated medicine products. Includes purified proteins and polypeptides. Excludes radiopharmaceuticals, vaccines, DNA products, allergenic excerpts, whole blood, or tube derivations.

Analytical Methods [1]

Analytical styles are essential for detecting, separating, and characterizing contaminations in Medicinal's. crucial way includes sample selection, testing chromatographic conditions, and optimizing system robustness.

1. **Reference Standard Method:** Serve as marks for medicine safety and quality. Applied to APIs, excipients, contaminations, declination products, and intercedes.
2. **Spectroscopic Methods:** UV-Vis Spectroscopy Measures chastity and attention using Beer-Lambert law.
   - **Infrared spectroscopy:** Infrared (IR) Spectroscopy Analyses functional groups via near, medial, and far-IR regions.
   - **Nuclear Magnetic Resonance Spectroscopy (NMR):** Nuclear glamorous Resonance (NMR) Provides structural characterization; limited quantitative use.
   - **Mass Spectroscopy:** Mass Spectrometry (MS) Identifies molecular weight and structure; limited quantitative use.
3. **Separation Techniques:** Chromatographic & Separation ways HPLC Separates composites using normal/rear phase with sensors (PDA, luminescence, refractive indicator, etc.)
4. **Characterization Methods:** Birth extraction Solid-phase extraction (SPE) Liquid-liquid extraction (LLE) Supercritical fluid birth (SFE) Hyphenated ways combine separation with discovery for detailed analysis LC-MS/GC-MS descry and quantify trace contaminations, metabolites, and declination products LC-UV, LC-NMR, LC-pater-MS Structural characterization after insulation.
5. **Isolation methods:** Chromatographic and non-chromatographic styles are used to insulate contaminations SPE, LLE, SFE Capillary Electrophoresis, SFC, HPLC, HPTLC, TLC, Column Chromatography, Flash Chromatography.



Specification for Impurities: The permissible situations of contaminations are defined in guidelines for new pharmaceutical substances. Stability studies, chemical development, and batch analyses help prognosticate implicit pollutants. Defences for including banning specific contaminations must consider Safety and clinical development batch data. contamination profile from the proposed marketable process.

Identification and structure elucidation of impurities [4]: Its contamination profiling is essential for quality assurance. cooperative sweats involve analytical druggists (separation & discovery) Pharmaceutical experimenters (expression

impact) Synthetic organic druggists (declination geste ways used Spectroscopic NMR, IR, Raman, MS, X-ray crystallography, Separation HPLC (primary system), GC, CE, IC, TLC birth contamination biographies help track changes in conflation or expression.



Fig 3: Identification of Impurities

Qualification of Impurities [4]: Qualification ensures the natural safety of an contamination. good contaminations Present in medicine substances with thorough safety/clinical studies. Significant metabolites observed in beast or mortal studies. Qualification depends on diurnal lozenge, patient demographics, route of administration, treatment duration Scientific literature data, QSAR modelling, and *in vitro* genotoxicity studies.



Fig 4: Qualification of Impurities

Reporting of Impurities [7]: Reporting thresholds define when a contamination must be reported. All results should be numerical, not qualitative. Contaminations should be enciphered (alphabetic/numeric) and presented as total contaminations if above threshold. Rounding rules.

Stability Studies [1]

Stability testing evaluates a medicine's capability to maintain its physical, chemical, and natural parcels over time under environmental stresses similar as temperature, moisture, and light. The results companion storehouse conditions and ensure product safety and efficacity. Types of Stability Studies

1. **Long-term stability testing (real-time testing):** Conducted under normal storehouse conditions for over to 12 months per ICH QIA (R2). Includes storehouse, transportation, and operation conditions. Sensitive medicines may bear lower temperature storehouse.
2. **Accelerated stability testing:** (generally 3-6 months) under inflated conditions to prognosticate long-term stability. Support product launch and process changes. Data helps assess goods of short-term diversions during conveyance.
3. **Force Degradation Study:** Purpose develop logical styles, understand stability, identify declination pathways, and determine optimal phrasings. Respectable declination for system confirmation 5-20; typical medicine patch stability threshold ≥ 90. Stress Conditions Applied Hydrolytic Acid (HCl or H2SO4, 0.1-IM)/Base (NaOH or KOH, 0.1-IM) Oxidative Hydrogen peroxide, essence ions, oxygen, radical inaugurators Photolytic UV or fluorescent light exposure (≥ 1.2 million lux, 200 Wh/m ²) Thermal Sot and wet heat (solid medicines products); dry heat (liquid products).



Fig 4: Forced Degradation Study

Applications and Significance of Impurity Profiling: Impurity profiling is pivotal for assessing the quality, safety, and energy of pharmaceutical substances whether synthetically produced, attained from natural products, or deduced via recombinant ways. It allows for the identification and junking of uninvited substances from medicine products, including anaesthetics, steroids, and other APIs. Crucial senses

1. Identification and Quantification Determines the type and quantum of contaminations present in a medicine product.
2. Regulatory Compliance ensures contamination situations cleave to ICH guidelines, supporting medicine enrolment and blessing.
3. Analytical Optimization helps determine whether contaminations arise from Manufacturing-related Organic, inorganic, residual detergents expression-related declination Lozenge form, system, environmental impurity. Other sources Enantiomeric, polymorphic, genotoxic contaminations.
4. Process and expression enhancement conflation-related contaminations May bear indispensable synthetic routes or safer reagents. expression-related contaminations Acclimate excipients or environmental conditions to maintain API stability. declination-related contaminations linked through stress testing and long-term stability studies.

Table 1: Application and Significance of Impurity Profiling

Drug	Impurity	Method
Amphotericin B	Tetraenes	UV spectroscopy
Atropine sulphate	Apo atropine	UV spectroscopy
Cloxacillin	N, N dimethyl aniline	GC
Dextrose	5 hydroxyl methyl furfurals	UV spectroscopy
Doxorubicin HCL	Acetone and ethanol	GC
Ethambutol HCL	2 amino butanol	TLC
Fluorescence sodium	Dimethyl formamide	GC
Framycetin sulphate	Neamine	TLC
Mercaptopurine	Hypoxanthine	UV spectroscopy
Deferesirox	Deferesirox A and B	HPLC-UV
Dup941	PC, SL, LS	LC-UV diode array
Trinitrotoluene	2, 4-dinitrotoluene	GC-MS
Lumefantrine	Desbenzylketo derivative	HPLC-DAD/UV-ESI/MS
Pholcodine	Pholcodine A, B, C	LC-ESI-MS
Mycophenolate mofetil	Mycophenolic acid	LC/DAD/LC/MS/MS

References

1. Jadhav GP, Kasture VS, Pawar SS, Vadgaonkar AR, Lodha AP, Tuse SK, *et al*. Drug impurity profiling: A scientific approach. Journal of Pharmacy Research. 2014;8(6):696-706.
2. U.S. Food and Drug Administration. Guidance for industry: ANDAs—Impurities in drug substances. Revision 1. Silver Spring (MD): FDA; 2009 [cited 2025 Oct 13]. Available from: https://www.fda.gov
3. Bari SB, Kadam BR, Jaiswal YS, Shirkhedkar AA. Impurity profile: Significance in active pharmaceutical ingredients. Eurasian Journal of Analytical Chemistry. 2007;2(1):32-53.
4. International Council for Harmonisation (ICH). Q3A(R2): Impurities in new drug substances. Geneva: ICH; 2006 [cited 2025 Oct 13]. Available from: https://database.ich.org/sites/default/files/Q3A%28R2%29%20Guideline.pdf
5. International Council for Harmonisation (ICH). Q3C(R6): Impurities: Guideline for residual solvents. Geneva: ICH; 2016 [cited 2025 Oct 13]. Available from: https://database.ich.org/sites/default/files/Q3C-R6_Guideline.pdf
6. International Council for Harmonisation (ICH). Q3D(R2): Guideline for elemental impurities. Geneva: ICH; 2022 [cited 2025 Oct 13]. Available from: https://database.ich.org/sites/default/files/Q3D-R2_Guideline.pdf
7. International Council for Harmonisation (ICH). Q1A(R2): Stability testing of new drug substances and products. Geneva: ICH; 2003 [cited 2025 Oct 13]. Available from: https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf